Novel Covid Anti-Viral Therapeutics

Description

This technology is a series of small molecules with potent anti-viral effects specifically designed for SARS-CoV-2 infections. The GSU compounds showed remarkable anti-viral activity against SARS-CoV-2 infections without in vivo toxicity in mouse models and exhibiting favorable biopharmaceutical properties, these compounds showcase significant promise in reducing COVID-19 infections.

As of April 2024, more than 884 million cases of COVID-19, caused by SARS-CoV-2 infection, have been reported globally, including more than 7 million deaths. New variants of the virus continue to emerge while the COVID-19 vaccine declines over time. It is estimated that the Delta variant has been 80% to 90% more transmissible than the Alpha variant. Around 25% of the COVID-19 cases in the U.S. were caused by a new variant called KP.3 in the past 3 months.

While Covid-19 vaccines continue to be developed to prevent infection, there is also a need to treat those patients who are not vaccinated or who develop infection despite being vaccinated. Current treatments are expensive, have low efficacy, interfere with common medications, need to be administered in a hospital setting, or only effective for a subset of cases. There is a need for the development of better Covid-19 treatments.

Benefits

Potent: 92-99% decrease in Covid 19 infection after treatment demonstrated in-vivo.
Anti-Inflammatory: Robust anti-inflammatory effects tailored for SARS-CoV-2 infections, addressing the immune response imbalances associated with COVID-19. This targeted potency contributes to mitigating inflammation-related complications and enhancing patient outcomes.
Safe: Demonstrated low to no in vivo toxicity in mouse models.
Optimized: The compounds exhibit favorable biopharmaceutical properties in mouse models, positioning them as promising candidates for further development.

Applications